Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Average Rating of “Moderate Buy” by Brokerages

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has received an average recommendation of “Moderate Buy” from the twenty-four ratings firms that are presently covering the firm, Marketbeat reports. Ten equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $802.1818.

REGN has been the subject of a number of research reports. Canaccord Genuity Group reduced their price objective on Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating for the company in a research report on Tuesday, May 19th. Morgan Stanley increased their price objective on Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the stock an “equal weight” rating in a report on Friday, July 31st. Leerink Partners raised their price objective on shares of Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the company a “market perform” rating in a research report on Monday, August 17th. Guggenheim lifted their target price on shares of Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. Finally, Benchmark raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 target price for the company in a research report on Tuesday, July 7th.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: RBC said Regeneron is increasingly likely to retain key patent protection for Eylea HD, a major commercial product. Preserving exclusivity could help protect revenue and earnings from biosimilar competition. Regeneron Pharmaceuticals More Likely to Retain Eylea HD Patent, RBC Says
• Positive Sentiment: HSBC raised its price target on REGN to $920 from $800 and maintained a Buy rating, implying substantial upside from the referenced share price. The move signals improved confidence in Regeneron’s outlook. HSBC Raises Regeneron Price Target
• Neutral Sentiment: A reported September short-interest figure of zero shares is not actionable because it is inconsistent with normal market data and produces a zero-day short-interest ratio.
• Negative Sentiment: Multiple law firms are promoting a securities class action against Regeneron, with a September 14 deadline for investors to seek lead-plaintiff status. The repeated notices add reputational and potential legal-cost risks, although they largely repeat the same lawsuit information rather than announce a new development. Regeneron Investor Deadline and Class Action Lawsuit
• Negative Sentiment: The lawsuit stems from the failure of a Phase 3 melanoma trial involving the Fianlimab-Libtayo therapy and allegations that Regeneron minimized statistical and protocol risks, including issues affecting progression-free-survival analysis. The trial failure reportedly erased about $11 billion in market value and raises concerns about the company’s pipeline and disclosure practices. Regeneron Clinical-Trial Risk Disclosure Lawsuit

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Kathryn Guarini sold 400 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total transaction of $340,000.00. Following the completion of the sale, the director directly owned 603 shares in the company, valued at $512,550. This represents a 39.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Arthur F. Ryan sold 200 shares of the firm’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total value of $130,030.00. Following the completion of the sale, the director directly owned 17,303 shares in the company, valued at approximately $11,249,545.45. This represents a 1.14% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 4,146 shares of company stock worth $3,432,488 over the last ninety days. Company insiders own 6.97% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in REGN. Tidal Investments LLC increased its position in Regeneron Pharmaceuticals by 10.7% during the second quarter. Tidal Investments LLC now owns 43,896 shares of the biopharmaceutical company’s stock worth $27,371,000 after acquiring an additional 4,244 shares during the period. National Pension Service boosted its holdings in Regeneron Pharmaceuticals by 2.2% in the 2nd quarter. National Pension Service now owns 379,815 shares of the biopharmaceutical company’s stock valued at $236,830,000 after purchasing an additional 8,264 shares during the period. Krensavage Asset Management LLC boosted its holdings in Regeneron Pharmaceuticals by 50.0% in the 2nd quarter. Krensavage Asset Management LLC now owns 6,000 shares of the biopharmaceutical company’s stock valued at $3,741,000 after purchasing an additional 2,000 shares during the period. Engineers Gate Manager LP grew its position in Regeneron Pharmaceuticals by 4,309.4% in the 2nd quarter. Engineers Gate Manager LP now owns 15,918 shares of the biopharmaceutical company’s stock worth $9,926,000 after purchasing an additional 15,557 shares during the last quarter. Finally, Cidel Asset Management Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 7.8% during the 2nd quarter. Cidel Asset Management Inc. now owns 775 shares of the biopharmaceutical company’s stock worth $483,000 after purchasing an additional 56 shares during the period. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $781.49 on Friday. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals has a 1-year low of $541.00 and a 1-year high of $859.34. The stock’s fifty day simple moving average is $754.93 and its 200-day simple moving average is $720.58. The company has a market capitalization of $80.46 billion, a price-to-earnings ratio of 19.32, a P/E/G ratio of 1.56 and a beta of 0.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.16 by $4.13. The business had revenue of $4.29 billion during the quarter, compared to analyst estimates of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The firm’s revenue was up 16.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $12.81 earnings per share. On average, sell-side analysts predict that Regeneron Pharmaceuticals will post 44.25 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, August 31st. Investors of record on Tuesday, August 18th were issued a $0.94 dividend. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date was Tuesday, August 18th. Regeneron Pharmaceuticals’s payout ratio is 9.29%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses technologies involving genetics, antibodies and other biologic treatments to advance therapies in areas such as eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease and rare disorders.

Regeneron’s marketed medicines include EYLEA and EYLEA HD for retinal diseases, Libtayo for certain cancers, Praluent for cardiovascular disease, Evkeeza for homozygous familial hypercholesterolemia and Veopoz for a rare immune disorder.